Caligan Partners
Caligan Partners reported 26 stocks worth $1.6B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (24.6%), LQDA (15.0%) and ABVX (9.4%). Compared with Q2 2026, the fund opened new positions in OBX, EPRX and TCGX, added to ADMA, IMCR and AVTX, trimmed IRD and ARTV and sold out of XENE and MBX.
Latest filing: what Caligan Partners did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() RVMD Revolution Medicines Inc | $403M | 24.6% | 2M | No change | 7 of 8 | |
| 2 | ![]() LQDA Liquidia Corporation | $246M | 15.0% | 8.1M | No change | 8 of 8 | |
| 3 | ![]() ABVX Abivax SA | $154M | 9.4% | 1.6M | No change | 8 of 8 | |
| 4 | ![]() PCVX Vaxcyte Inc | $125M | 7.6% | 2.2M | No change | 4 of 8 | |
| 5 | ![]() EXEL Exelixis Inc | $90.7M | 5.5% | 1.6M | No change | 8 of 8 | |
| 6 | ![]() TNGX Tango Therapeutics Inc | $62.4M | 3.8% | 2.5M | No change | 4 of 8 | |
| 7 | ![]() ADMA Adma Biologics Inc | $58.9M | 3.6% | 5.9M | +150K (+3%) | 5 of 8 | |
| 8 | ![]() IMCR Immunocore Hldgs PLC | $50.6M | 3.1% | 1.7M | +291K (+21%) | 2 of 8 | |
| 9 | ![]() AVTX Avalo Therapeutics Inc | $50.1M | 3.1% | 3.3M | +104K (+3%) | 5 of 8 | |
| 10 | ![]() LBRX LB Pharmaceuticals Inc | $49.6M | 3.0% | 1.5M | +72K (+5%) | 3 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Caligan Partners 13F FAQ
What does Caligan Partners own?
Caligan Partners reported 26 stocks worth $1.6B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (24.6%), LQDA (15.0%) and ABVX (9.4%). The table above lists every position in the filing (the top 10 without an account).
What did Caligan Partners buy and sell in Q3 2026?
Compared with Q2 2026: 3 new positions, 10 added to, 2 trimmed and 2 sold out. New positions include OBX, EPRX and TCGX. It sold all of XENE and MBX.
When will Caligan Partners file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Caligan Partners's portfolio worth?
The Q3 2026 filing reports $1.6B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.




















